[yaocajun] has an annual sales volume of 1.7 billion, and the new indications of Hengrui King brand products are reported for production. Yichang humanwell mainstream fentanyl product line will be equipped? PD-1 circuit will add a new surge; another blank market in China will be filled

Highlights: 1 Yichang humanwell is equipped with mainstream fentanyl series products! 2 The world's first anti EGFR monoclonal antibody, Merck again hit the blank market of targeted treatment in the field of head and neck squamous cell carcinoma! 3 Hengrui sells 1.7 billion trump brand products annually, and new indications are reported for production! 4 Add strength players to PD-1 circuit and expect to speed in corners? This week, the novel coronavirus pneumonia is good news The drug administration and approval of the national drug administration is also proceeding quickly More details and details are also given to you in this week's new trial This week, the new trend of nmpa approval, cde25 reports production drug acceptance number (14 varieties) for status update, among which the most concerned ones are alfentanil hydrochloride of Yichang humanwell and cetuximab of Merck Details are as follows: alfentanil hydrochloride injection alfentanil hydrochloride injection is a powerful analgesic for anesthesia, which is suitable for short-term surgery It was first listed in the Netherlands in 1983 and introduced into the U.S market in 1987 It has been used in clinical safety for 30 years and has not been listed in China If alfentanil hydrochloride goes on the market successfully, Yichang humanwell will be equipped with mainstream fentanyl products, including fentanyl, remifentanil, sufentanil and alfentanil In addition, in addition to humanwell pharmaceutical, Jiangsu Enhua Pharmaceutical Co., Ltd has submitted an application for listing in October 2019 Cetuximab - the world's first anti EGFR monoclonal antibody, cetuximab, was approved in China in 2004 In September 2019, nmpa officially approved cetuximab for the first-line treatment of ras gene wild-type metastatic colorectal cancer At present, it has been approved in more than 100 countries around the world, mainly for the treatment of Ras wild-type metastatic colorectal cancer and head and neck squamous cell carcinoma It is speculated that the indication of this declaration is squamous cell carcinoma of the head and neck If approved this time, it is expected to fill the gap of targeted treatment in the field of head and neck squamous cell carcinoma and benefit more patients This week, CDE reviewed and approved the new acceptance CDE accepted a total of 60 drugs (based on the acceptance number) The application classification is still based on chemical drugs, involving 52 varieties Details are as follows: apatinib Hengrui sales of 1.7 billion yuan of class 1 new drugs Apatinib trade name: Etan, is an oral small molecule anti angiogenesis inhibitor independently developed by Hengrui In 2014, it was approved to treat patients with advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma who had undergone at least two kinds of systematic chemotherapy before or relapsed At present, only one indication of the drug has been approved for marketing, but it is Hengrui's trump brand product, with a sales volume of about 1.7 billion yuan in 2018 Apatinib's second indication is intended to be used in the second-line treatment of liver cancer, which has been declared for listing and is expected to bring more surprises to Hengrui Sepalimab injection: the first recombinant all human anti-PD-1 monoclonal antibody screened by transgenic rat platform in China Sepalimab injection, formerly known as gls-010 injection, is commissioned by Yuheng biology to develop Yaoming biology, led by Peking University Cancer Hospital and participated in the clinical trial declaration by a number of clinical tumor research institutions in various provinces and cities of the country, with complete independent intellectual property rights The demand of Chinese patients for domestic innovative anti-tumor drugs is very large At present, the domestic PD-1 / L1 track competition is very fierce In the face of strong competitors around, Yuheng bio, on the one hand, relies on the domestic mature and perfect business system, and on the other hand, cooperates with the production technology of international certification level, can it "overtake in a corner" break its own world? Let's see (list of current domestic PD-1 / PD-L1) data source: drug intelligence data, enterprise announcement and other network public data information sources: drug intelligence data, enterprise announcement and other network public information sources With high integration, in-depth analysis and intelligent intelligence of pharmaceutical intelligence data, the intelligent tool platform for pharmaceutical data has been specially built for VIP enterprise customers, covering core data such as drug registration, hospital sales, drug reports, enterprise reports, clinical trials, drug listing, drug bid winning, device listing, drug sales, etc., and providing all-round access to enterprise users from production, research and development, sales, and use And other information channels in various links to help enterprises in R & D and decision-making Mengmeng statement: this view only represents the author and does not represent the position of yaozhi.com You are welcome to exchange and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.